Cytogenetic characteristics and FAB classifications of 44 de novo AML patients with high EVI1 and/orMDS1-EVI1 expression
| Patient no. and group . | Karyotype4-150 . | FAB4-151 . | Relative expression ofEVI1‡ . | Relative expression of MDS1-EVI1‡ . | MDS1 expression4-153 . |
|---|---|---|---|---|---|
| Group I, EVI1+and MDS1-EVI1− | |||||
| 8 | 46,XX,r(2)(p?q?),add(5)(q1?3),der(11)t(11;12)(q1?4;p13), der(12)t(11;12) (q1?4;p13)del(12)(p13p13)[23]/45,idem, −7[3]/46,XX[6] | Mx | 1 176 | 1 | − |
| 9 | 46,XX[68] | M4 | 3 821 | 1 | − |
| 10 | 46,XX,t(1;6)(p32;q24or25),del(2)(q34)[33]/46,XX[1] | M0 | 4 420 | 1 | − |
| 11 | 43-45,XY,−3[19],−5[4],der(5)t(5;17)(q1?3;q2?1)[15], −7[19],i(8)(q10)[11], −11[13],−17[19],ider(19)(q10)add (19)(q13)[18],add(2)(q1?3)[13]/ 46,XY[2] | M6 | 4 705 | 1 | − |
| 12 | 45,XY,inv(3)(q12q26.2),−7[20] | M0 | 19 552 | 1 | − |
| 13 | 46,XX,−7[27]/46XX[3] | M4 | 24 920 | 1 | − |
| Group II, EVI1+ and MDS1-EVI1+ | |||||
| 14 | 46,XY[23] | M5 | 53 | 220 | − |
| 15 | 46,XX,der(6)t(6;11)(p12;q23),der(11)t(6;11)add(11)(p15)[4]/46,XX[6] | M4 | 55 | 685 | − |
| 16 | 47,XY,+8[4]/46,XY[16] | M5 | 93 | 220 | − |
| 17 | 47,XX,+13[58]/46,XX[1] | M5 | 141 | 12 810 | − |
| 18 | 46,XX[34] | M1 | 149 | 340 | − |
| 19 | 46,XY,−7,add(12)(p12)[13]/46,XY[15] | M1 | 179 | 95 950 | + |
| 20 | 45,XY,−7,t(7;8)(q22;p11)[25] | M5 | 308 | 12 766 | + |
| 21 | 46,XX,t(9;22)(q34;q11)[10] | M2 | 389 | 15 936 | + |
| 22 | 46,XX,t(9;11)(q34;q23)[5] | M1 | 578 | 15 771 | − |
| 23 | 46,XY,t(3;3)(q2?3;q26),−7,t(10;20)(p13;q11),+r.ishr(7)(cen7+)[5]/46, idem,i(21)(q10)[8]/46,idem,ins(12;?)(q1?5;?) [2]/46,XY[4] | Mx | 699 | 25 532 | + |
| 24 | 45,XY,−7[5]/46XY[4] | M2 | 690 | 1 716 | + |
| 25 | 46,XY,t(9;22)(q34;q11)[22] | M2 | 2 436 | 14 067 | − |
| 26 | 46,XX,del(7)(q22)[41],46,XX[1] | M2 | 2 513 | 231 395 | + |
| 27 | 46,XX[10] | M5 | 2 947 | 32 996 | + |
| 28 | 46,XY,t(6;11)(q25;q23)[38] | M1 | 3 083 | 156 956 | + |
| 29 | 46,XY[40] | M5 | 3 456 | 151 085 | + |
| 30 | 45,XY,−7,t(9;11)(p21;q23)[33] | M4 | 3 916 | 29 944 | − |
| 31 | 46,XY,t(11;19)(q23;p13)[11] | M4 | 4 513 | 31 542 | + |
| 32 | 46,XX,t(2;9;11)(p13;p22;q23)[20] | M4 | 4 804 | 21 174 | + |
| 33 | 46,XX,t(9;11)(p21;q23)[10] | M5 | 7 383 | 25 268 | + |
| 34 | 45,XY,−7[33]/46,XY[8] | M3 | 9 541 | 15 286 | + |
| 35 | 45,XY,inv(3)(q22q26),−7[25] | M5 | 12 119 | 551 | − |
| 36 | Failure | M5 | 16 845 | 5 349 | + |
| 37 | 46,XY,t(6;11;18)(q26;q23;q23)[23] | M5 | 17 560 | 150 562 | + |
| 38 | 46,XY,der(3)del(3)(p1?4q2?4)add(3)(q24),del(18)(q22q24)[5]/46,idem, del(6)(q11q27)[2],del(7)(q2?2q36)[cp3]/45, idem,−7[9]/46,XY[10] | M0 | 19 082 | 28 725 | − |
| 39 | 45,XX,inv(3)(q22q26),−7[31]/46,XX[1] | M5 | 27 554 | 3 040 | − |
| Group III, EVI1− and MDS1-EVI1+ | |||||
| 40 | 46,XX[31] | M5 | 1 | 53 | − |
| 41 | 46,XY[32]. | M2 | 1 | 67 | − |
| 42 | 46,XX,inv(16)(p13q22)[8]/47,XX,idem,+22[47] | M4 | 1 | 70 | − |
| 43 | 46,XY,del(12)(q11q21),t(15;17)(q22;q11)[65] | M3 | 1 | 73 | − |
| 44 | 46,XX[37] | M2 | 1 | 88 | − |
| 45 | 47,XX,+21[22]/46,XX[7] | M2 | 1 | 129 | − |
| 46 | 46,XY,del(6)(q14q16),t(10;17)(p15;q21),?der(11)[7]/46,XY[3] | M1 | 1 | 151 | − |
| 47 | 45,X,−Y,t(8;21)(q22;q22),−13[27]/46,XY[1] | M2 | 1 | 165 | − |
| 48 | 44,XX,add(2),−5,−7[2]/45,XX,dic(5;7)(p1;p1)del(5)(q3?1q3?3)[2]/37– 42,XX,der(1)t(1;4)(q1?;p1?),−4,dic(5;7)(p1;p1)del(5)(q3?1q3?3), del(8)(p?21;p2?2),inv(10)(p12q?23),−15,add(15)(q2?3),dic(17;?) (p11;?),−18,del( 20)(q11q13)/46,XX[13] | M3 | 1 | 209 | − |
| 49 | 46,XX,inv(11)(p15q13),t(15;17)(q22;q12)[28]/46,XX[1] | M3 | 1 | 209 | − |
| 50 | 46,XY[52] | M3 | 1 | 296 | − |
| 51 | 46,XX[26] | M1 | 1 | 28 725 | − |
| Patient no. and group . | Karyotype4-150 . | FAB4-151 . | Relative expression ofEVI1‡ . | Relative expression of MDS1-EVI1‡ . | MDS1 expression4-153 . |
|---|---|---|---|---|---|
| Group I, EVI1+and MDS1-EVI1− | |||||
| 8 | 46,XX,r(2)(p?q?),add(5)(q1?3),der(11)t(11;12)(q1?4;p13), der(12)t(11;12) (q1?4;p13)del(12)(p13p13)[23]/45,idem, −7[3]/46,XX[6] | Mx | 1 176 | 1 | − |
| 9 | 46,XX[68] | M4 | 3 821 | 1 | − |
| 10 | 46,XX,t(1;6)(p32;q24or25),del(2)(q34)[33]/46,XX[1] | M0 | 4 420 | 1 | − |
| 11 | 43-45,XY,−3[19],−5[4],der(5)t(5;17)(q1?3;q2?1)[15], −7[19],i(8)(q10)[11], −11[13],−17[19],ider(19)(q10)add (19)(q13)[18],add(2)(q1?3)[13]/ 46,XY[2] | M6 | 4 705 | 1 | − |
| 12 | 45,XY,inv(3)(q12q26.2),−7[20] | M0 | 19 552 | 1 | − |
| 13 | 46,XX,−7[27]/46XX[3] | M4 | 24 920 | 1 | − |
| Group II, EVI1+ and MDS1-EVI1+ | |||||
| 14 | 46,XY[23] | M5 | 53 | 220 | − |
| 15 | 46,XX,der(6)t(6;11)(p12;q23),der(11)t(6;11)add(11)(p15)[4]/46,XX[6] | M4 | 55 | 685 | − |
| 16 | 47,XY,+8[4]/46,XY[16] | M5 | 93 | 220 | − |
| 17 | 47,XX,+13[58]/46,XX[1] | M5 | 141 | 12 810 | − |
| 18 | 46,XX[34] | M1 | 149 | 340 | − |
| 19 | 46,XY,−7,add(12)(p12)[13]/46,XY[15] | M1 | 179 | 95 950 | + |
| 20 | 45,XY,−7,t(7;8)(q22;p11)[25] | M5 | 308 | 12 766 | + |
| 21 | 46,XX,t(9;22)(q34;q11)[10] | M2 | 389 | 15 936 | + |
| 22 | 46,XX,t(9;11)(q34;q23)[5] | M1 | 578 | 15 771 | − |
| 23 | 46,XY,t(3;3)(q2?3;q26),−7,t(10;20)(p13;q11),+r.ishr(7)(cen7+)[5]/46, idem,i(21)(q10)[8]/46,idem,ins(12;?)(q1?5;?) [2]/46,XY[4] | Mx | 699 | 25 532 | + |
| 24 | 45,XY,−7[5]/46XY[4] | M2 | 690 | 1 716 | + |
| 25 | 46,XY,t(9;22)(q34;q11)[22] | M2 | 2 436 | 14 067 | − |
| 26 | 46,XX,del(7)(q22)[41],46,XX[1] | M2 | 2 513 | 231 395 | + |
| 27 | 46,XX[10] | M5 | 2 947 | 32 996 | + |
| 28 | 46,XY,t(6;11)(q25;q23)[38] | M1 | 3 083 | 156 956 | + |
| 29 | 46,XY[40] | M5 | 3 456 | 151 085 | + |
| 30 | 45,XY,−7,t(9;11)(p21;q23)[33] | M4 | 3 916 | 29 944 | − |
| 31 | 46,XY,t(11;19)(q23;p13)[11] | M4 | 4 513 | 31 542 | + |
| 32 | 46,XX,t(2;9;11)(p13;p22;q23)[20] | M4 | 4 804 | 21 174 | + |
| 33 | 46,XX,t(9;11)(p21;q23)[10] | M5 | 7 383 | 25 268 | + |
| 34 | 45,XY,−7[33]/46,XY[8] | M3 | 9 541 | 15 286 | + |
| 35 | 45,XY,inv(3)(q22q26),−7[25] | M5 | 12 119 | 551 | − |
| 36 | Failure | M5 | 16 845 | 5 349 | + |
| 37 | 46,XY,t(6;11;18)(q26;q23;q23)[23] | M5 | 17 560 | 150 562 | + |
| 38 | 46,XY,der(3)del(3)(p1?4q2?4)add(3)(q24),del(18)(q22q24)[5]/46,idem, del(6)(q11q27)[2],del(7)(q2?2q36)[cp3]/45, idem,−7[9]/46,XY[10] | M0 | 19 082 | 28 725 | − |
| 39 | 45,XX,inv(3)(q22q26),−7[31]/46,XX[1] | M5 | 27 554 | 3 040 | − |
| Group III, EVI1− and MDS1-EVI1+ | |||||
| 40 | 46,XX[31] | M5 | 1 | 53 | − |
| 41 | 46,XY[32]. | M2 | 1 | 67 | − |
| 42 | 46,XX,inv(16)(p13q22)[8]/47,XX,idem,+22[47] | M4 | 1 | 70 | − |
| 43 | 46,XY,del(12)(q11q21),t(15;17)(q22;q11)[65] | M3 | 1 | 73 | − |
| 44 | 46,XX[37] | M2 | 1 | 88 | − |
| 45 | 47,XX,+21[22]/46,XX[7] | M2 | 1 | 129 | − |
| 46 | 46,XY,del(6)(q14q16),t(10;17)(p15;q21),?der(11)[7]/46,XY[3] | M1 | 1 | 151 | − |
| 47 | 45,X,−Y,t(8;21)(q22;q22),−13[27]/46,XY[1] | M2 | 1 | 165 | − |
| 48 | 44,XX,add(2),−5,−7[2]/45,XX,dic(5;7)(p1;p1)del(5)(q3?1q3?3)[2]/37– 42,XX,der(1)t(1;4)(q1?;p1?),−4,dic(5;7)(p1;p1)del(5)(q3?1q3?3), del(8)(p?21;p2?2),inv(10)(p12q?23),−15,add(15)(q2?3),dic(17;?) (p11;?),−18,del( 20)(q11q13)/46,XX[13] | M3 | 1 | 209 | − |
| 49 | 46,XX,inv(11)(p15q13),t(15;17)(q22;q12)[28]/46,XX[1] | M3 | 1 | 209 | − |
| 50 | 46,XY[52] | M3 | 1 | 296 | − |
| 51 | 46,XX[26] | M1 | 1 | 28 725 | − |
Group IV (EVI1− andMDS1-EVI1−) contained 275 of the 319 patients analyzed.
According to the ISCN.22
Mx indicates FAB not defined.
Values represent expression levels of EVI1 andMDS1-EVI1 as compared with the average values determined in 9 healthy bone marrow samples 2−δ δCt(see “Patients, materials, and methods”).
MDS1 expression was considered positive (+) when the Ct value was below 35.